Dr. Juan José Espinós

Specialist in Reproductive Endocrinology and Human Reproduction, Coordinator of the Reproductive Endocrinology Unit of the Hospital de la Santa Creu i Sant Pau and Coordinator of Obstetrics and Gynaecology in the Teaching Unit of this Hospital attached to the UAB.

“I wanted to put my own personal stamp on it, a way of performing reproduction in which the facts, i.e. the success in achieving a pregnancy and a healthy newborn, are just as important as the people who want to fulfil their wishes for motherhood.”

Dr Juan José Espinós is a specialist in Reproductive Endocrinology and Human Reproduction, Coordinator of the Reproductive Endocrinology Unit of the Hospital de la Santa Creu i Sant Pau and Coordinator of Obstetrics and Gynaecology in the Teaching Unit of this Hospital attached to the UAB.

 

He specialises in every aspect of reproductive medicine, and especially in topics involving Polycystic Ovary Syndrome and the relationship between life habits and reproduction.

 

His experience as founder, and director for over a decade, of the Assisted Reproduction Centre at the Clínica Sagrada Familia has given him experience that he wants to place at the service of FERTTY to help it become a benchmark for reproductive medicine.

 

His academic training took place in Barcelona, where he studied Medicine and Surgery at the UB, graduating with the qualification of excellent and the Extraordinary Award of Degree granted by the same university. He specialised in Gynaecology and Obstetrics at the Hospital de la Santa Creu i Sant Pau and completed his training by obtaining the degree of Doctor of Medicine from the UAB with a qualification of Excellent Cum Laude. To broaden his knowledge in the field of reproduction, he stayed at the Instituto Valenciano de Infertilidad in Madrid (2005), at the San Barnabas Medical Center (IRSM) (New Jersey, USA) and at the New York University Fertility Center (New York, USA)

Interview
WHY DID YOU BECOME A FERTILITY EXPERT?

It was more the consequence of a series of circumstances rather than anything premeditated. In my early days I was passionate about reproductive endocrinology, pathologies such as polycystic ovary, hyperprolactinemia or hypothalamic amenorrhea associated with weight or stress were an unresolved challenge. Likewise, contraception or menopause were on the rise. Little by little we have been controlling most of these problems, and on the other hand, fertility has acquired a remarkable social importance, largely due to social changes, which work against it.

WHY ARE YOU PROUD TO WORK AT FERTTY?

This was a project that I had always wanted to set in motion: to put my own personal stamp on a way of performing reproduction in which the actions, that is, the success in terms of achieving pregnancy and a healthy newborn, are as important as the people who want wish to fulfill their wishes of motherhood.

WHAT IS YOUR ATTITUDE TO PATIENT MANAGEMENT?

I am one of those professionals who like to be direct and face up to situations, however complicated they may be, with a positive spirit. I don’t usually beat around the bush.  I like to be realistic and not build castles in the air. People who come to me for help know that I will be involved 100% or more if necessary, and that I am the first to rejoice in successes and mourn failures. I like to think that I am a part of the lives of the people I deal with.

HAVE THERE BEEN PATIENTS WHO INSPIRE YOU?

There have been women with a capacity for suffering in the face of adversity that is admirable, so I always have fond memories of them. Failures, one after the other, and they are still going strong, until they have achieved their goal. And all this without losing their trust in me. That is one of the most precious gifts we can receive, the knowledge that we enjoy the complete trust of the people who come to our clinic.

HOW DO YOU SPEND YOUR FREE TIME?

Unfortunately I don’t have much of that. That’s what my family and friends complain about. I like to run, which is when I usually get my ideas straight and clear my mind. I also love reading, though I can only do it in the summer, on holiday. I love all types of sports. Oh, and food. I’m also very interested in gastronomy.

HOW WOULD YOU DESCRIBE YOUR PERSONALITY?

Extrovert, sincere, trusting, sometimes too much. And a friend to my friends.

Scientific publications

 

Concentraciones séricas de insulina y andrógenos en mujeres con antecedentes de diabetes gestacional. J.J. Espinós, R. Corcoy, B. Roca, J. Rodríguez Espinosa y J. Calaf. Med Clin 1992, 12: 445‑448 IP: 1.258

 

Long-acting repeatable bromocriptine in the treatment of patients with microprolactinoma intolerant or resistant to oral dopaminergics. JJ Espinós, J. Rodriguez-Espinosa, SM Webb, J Calaf. Fertil Steril 1994; 62:926-31. IP: 4.167

 

Emergency contraception. Preliminary results of our program. JJ Espinós. Gispert, M. Vega, C. Vanrell, C. Aura, M. European Journal  of Contraception Reproductive Human Care. 1998, p.46 vol 3 (1) IP: 0.824

 

Safety and effectiveness of hormonal postcoital contraception: a prospective study. Espinós JJ, Senosiain R, Aura M, Vanrell C, Armengol J y cols. Eur J Cont Reprod H Care 1999; 4: 27-33. IP: 0.824

 

The role of matching menstrual data with hormonal measurements in evaluating effectiveness of postcoital contraception. Espinos JJ. Rodriguez-Espinosa J. Senosiain R. Aura M. Vanrell C. Gispert M. Vega C. Calaf J. Contraception 1999; 60:243-7. IP:2.327

What is the seminal exposition among women requiring emegency contraception? A prospective observational study. Espinós-Gómez JJSenosiain RMata AVanrell CBassas LCalaf J. Eur J Obst Gynecol Reprod Biol 2007; 131:57-60. IP: 1.565

 

Prevalence and predictors of abnormal glucose metabolim in Mediterranean women with polycystic ovary syndrome. Espinós JJ. Corcoy, R, Calaf, J Gynecol Endocrinol 2009;  25:199-204. IP: 1.360

 

Non conventional uses of human chrorionic gonadotropin (hCG) for ovulation induction: a systematic review and meta-analysis. Agramunt S, Martinez-Zapata M, Vazquez J, Requena A, Espinós JJ. Fertil Steril 2010, 94:156-6. IP: 3.122

 

Hirsutism scoring in polycystic ovary syndrome: concordance between clinicians and patients self-scoring. Espinós, JJ, Estadella J, Calaf, J, Checa, MA. Fertil Steril 2010; 94: 2815-6. IP: 3.122

 

Metabolic syndrome in Mediterranean women with polycystic ovary syndrome: when and how to predict its onset. Espinós-Gómez JJ, Rodriguez-Espinosa J , Ordóñez-Llano J, Calaf-Alsina  J. Gynecol Endocrinol, 2012; 28-264-8. IP: 1.360

 

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis. Checa MA, Espinós JJ, Requena A. Fertil Steril 2012; 97:1343-50. IP: 3.122

 

Effect of changes to cost and availability of emergency contraception on users’ profiles in an emergency department in Catalunya. Trilla C, Senosiain R, Calaf J, Espinós JJ. Eur J Contracept Reprod Health Care. 2014 Aug;19(4):259-65. IP: 1.835

 

Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia. Espinós JJ, Vanrell C, Urgell E, Calaf J. Gynecol Endocrinol (in press). IP: 1.360

 

Outcome and long term effects of pregnancy in women with hyperprolactinaemia. X. Ampudia, M. Puig‑Domingo, D. Schwarzstein, R. Corcoy, J.J. Espinós, J. Calaf‑Alsina y S. Webb. Eur J Obst Gynecol Reprod 1992; 46:101‑107. IP: 1.565

 

Hipotiroidismo: causa de galactorrea con normoprolactinemia. Albareda, M. Calaf, J. JJ Espinós. Corcoy, R. Revista Clínica Espanyola. 1998 P 405-406 Vol 198 (6). IP:0.734

 

Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. Coeling Bennink H, Fauser B, Out H y cols. Fertil Steril 1998; 69:19-25. IP: 4.167

The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO I group anovulation: evidence from a multicentre Study in Spain. Burgués S and the Spanish Collaborative Group. Hum Reprod 2001; 16:2525-32. IP: 3.773

 

Ovulation induction with a starting dose of  50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial. Calaf, J. Ruíz, JA. Romeu, A. Caballero, V. Cano, I. Gómez, JL. González, C. Rodríguez, FT. Study Group. Int J  Obst  Gynaecol 2003; 110: 1072-1077.  IP: 0.800

 

Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Checa MA, Requena A, Salvador C, Tur R, Callejo J, Espinos JJ, Fabregues F, Herrero J. Hum Reprod Update 2005; 11:375-90. IP:7.590

 

Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. Calaf J, López E, Millet A, Alcañiz J, Fortuny A, Vidal O, Callejo J,Escobar-Jiménez F, Torres E, Espinós JJ; Spanish Working Group for Hirsutism. J Clin Endocrinol Metab. 2007 Sep;92(9):3446-52. Epub 2007 Jun 12.IP: 6.325

 

Use of letrozole in assisted reproduction: a systematic review an meta-analysis. Requena, A. Herrero, J. Landeras, J. Navarro, E. Neyro, JL. Salvador, C. Tur, R. Callejo, J. Checa, MA. Farré, M. Espinós JJ. Fabregués, F. Graña-García, M. Hum Reprod Update; 2008, 14(6):571-582 IP: 7.590

 

Ovulation induction with minimal dose of follitropin alfa: a case series study. Bruna-Catalán I, Menabrito M, Oltra MF, Rodríguez JM, Jimenez C, Amselem C, Aura M, Herrero J, Espinós JJ y cols. Reprod Biol Endocrinol. 2011; 9:142. IP: 1.7

 

Genetic analysis does not confirm non-classifcal congenital adrenal hyperplasia in moret han a third of the women followed with this diagnosis. Alcantara-Aragon V, Martinez-Couselo S, Tundidor-Rengel D, Webb SM, Carreras G, Espinos JJ, Chico A, Blanco-Vaca F, Corcoy R. Hormones 2014, 13(4):585-587. IP: 1.24

 

Adherence to pelvic floor muscle training with or without vaginal spheres in women with urinary incontinence: a secondary analysis from a randomized trial. Porta Roda O, Díaz López MA, Vara Paniagua J, Simó González M, Díaz Bellido P and Espinós Gómez JJ. Int Urogynecol J 2016; 27(8):1185-91. IP: 1.961.

 

Efficacy and safety of follitropin alfa/lutropin  alfa in ART: a randomized controlled trial in poor ovarian responders. Humaidan P, Chin W, Rogoff D, D’Hooghe T
, Longobard S, Hubbard J, Schertz J on behalf of the ESPART Study Investigators. Hum Reprod 2017. IP: 4.621

 

Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia. Espinós JJ, Vanrell C, Gich I, Urgell E, Calaf J. Gunecol Endocrinol 2017. IP: 1.360

 

Weight decrease improves live birth rates in obese women undergoing IVF: a pilot study.  Espinós JJ, Polo A, Sanchez-Hernandez J, Bordas R, Pares P, Martinez O, Calaf J RBM Online 2017. IP: 3.249

 

Early skin metastasis of endometrial adenocarcinoma: Case report and review of the literature.” J.J. Espinós, E. Delgado, X. Matías, V García Patos. Cutis, 1993; 52: 109-111. IP: 0.800

 

Genital Herpes Simplex Virus Type 1: Case Report of Oro-genital Infection by Autotransmission. Peró M and Espinós JJ, J Genit Syst Disor 2016, 5:4. IP: 0.37